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Summary An immunohistochemical study has been carried out on fibre optic-biopsy specimens from
patients with small cell lung cancer (SCLC) who had either died within 3 months, or who had survived more
than 2 years. Long term survivors (LTS) were identified from completed clinical trials at major UK centres
and were matched for age and sex within the trial with short term survivors (STS). The panel of immunohis-
tochemical markers included those previously reported to be associated with prognosis, and reagents represen-
tative of both neuroendocrine and epithelial differentiation. A preliminary screen of 17 antibodies identified 11
as consistently reactive on paraffin-embedded material using streptavadin-biotin immunoperoxidase. Of 186
identified patients, 110 biopsy samples were retrieved. Of these, 70 gave sufficient material for analysis. All sec-
tions were scored by three observers without knowledge of the prognosis. The analysis failed to identify any
antigen whose expression was correlated with prognosis. We conclude that, in fibre-optic biopsy specimens,
immunohistochemical analysis does not add prognostic information in SCLC.
Small cell lung cancer SCLC is characterised by monomor-
phic, undifferentiated cells which typically show neuroendoc-
rine (NE) properties such as high levels of dopa decarboxy-
lase, creatinine kinase BB, neurone specific enolase (NSE)
and bombesin, and the presence of neurosecretory granules.
The tumour is usually disseminated at the time of diagnosis,
shows a dramatic response to chemotherapy and radiation,
but relapses quickly. Cure rates are extremely low with long-
term disease free survival expected in only 3-5% of cases
(Davis et al., 1984; Souhami & Law, 1990). Although for
many patients treatment is palliative, it might be possible to
increase cure rate by intensifying treatment in patients
identifiable as having better prognostic features at presenta-
tion. Clinical and biochemical information give considerable
prognostic information (Rawson & Peto, 1990; Souhami et
al., 1985) but studies relating histological subtype to prog-
nosis have given conflicting results (Hansen et al 1978;
Carney et al., 1981; Aisner et al., 1983; Vollmer et al., 1985;
Hirsch et al., 1988).
SCLC expresses antigens associated with both neuroendoc-
rine and epithelial differentiation (Souhami et al., 1991).
Several groups have attempted to relate antigen expression in
SCLC to clinical behaviour and prognosis (Allan et al., 1987;
Hamid et al., 1987; Martignone et al., 1989; Ruckdeschel et
al., 1991). The results have been variable. Conversely, it has
been suggested that NE features in lung adenocarcinoma are
associated with a better response to chemotherapy (Skov et
al., 1991). We have recently undertaken an analysis of long
term survival in SCLC treated in clinical trials in major
centres in the UK (Souhami & Law, 1990). These trials have
given us the opportunity to examine diagnostic biopsy
material immunohistochemically in an attempt to relate pat-
terns of antigen expression to prognosis.
Materials and methods
Patients with SCLC surviving more than' 2 years were
identified from trials forming part of a national study on
longevity in SCLC (Souhami & Law, 1990). The clinical
coordinators of the 12 trials carried out by the UK Medical
Research Council, the London Lung Cancer Group, and the
Edinburgh Department of Medical Oncology, were asked to
provide biopsy material for all those patients identified as
having survived in excess of 2 years. For each such patient a
further patient was identified, within the same study, who
had died within 3 months of entering the trial and who was
of the same sex and within 3 years of age. Those surviving
more than 2 years are referred to as long-term survivors
(LTS) and those dying early (within three months) are short-
term survivors (STS).
The original biopsy material was a fibre-optic bronchos-
copy specimen in every case. Of the 186 identified cases, 100
specimens were received. Of these, 54 were LTS and 56 STS.
On review of the 110 specimens in 70 the diagnosis was
confirmed and the material was found to be satisfactory (34
LTS and 36 STS). Details of the cases and the reasons for
exclusion are given in Table I. From this it can be seen that,
although only 70/186 samples were received and suitable for
analysis, there was no reason to suspect systematic bias in the
samples examined. Sufficient material for immunohis-
tochemical studies was present in all the cases.
The investigation was conducted in two stages. In the first,
a panel of antibodies was chosen and used to stain archival
material of the same quality as the study specimens. Details
of the screening panel are given in Table II. These antibodies
were chosen either because they recognised markers of NE
(HNK1, HNK 901, NSE and chromogranin) or epithelial
(LP34, HMFG2, SM3) differentiation, or because they recog-
nised antigens known to be expressed on SCLC and other
tumours (AUA1, MOC21, SWA4, SWA20, 123C3), or
because they had been previously suggested to correlate with
survival in patients with SCLC [HMFG2 (Allan et al., 1987),
MBR1 (Martignone et al., 1989), CEA (Ruckdeschel et al.,
1991), C terminal peptide of probombesin (Hamid et al.,
1987)], or in patients with other tumours [PC10 (Soomro &
Whimster, 1990; Hall et al., 1990), S100 (Fox et al.,
1989)].
This preliminary testing showed that some of the
antibodies were suitable for the definitive study (AUA1,
HMFG2, HNK1, LP34, PC1O, SWA20, MBR1, S100, NSE
Chromogranin and CEA). The other reagents gave no
specific staining on paraffin embedded sections of five cases
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Table I Details of patients and pathology specimens. LTS = Long
Term Survivors; STS = Short Term Survivors
LTS
Mean
STS
Mean
No. Age M/F No. Age M/F
Requested 186 93 62 3:2 93 60 3:2
Received 110 54 62 1:1 56 59.5 1:1
Adequate 70 34 60 1:1 36 59 1:0.9
Reasons for rejection
Insufficient material 15 18
Overfixation 4 1
Crush artefact 1 0
Erroneous diagnosis 0 1
Total 20 20
of SCLC, and one case of squamous carcinoma of the lung.
These reagents were therefore excluded from the further
analysis. Immunohistology was carried out on 4ytM paraffin-
embedded sections. These were treated with fresh hydrogen
peroxide, to block endogenase peroxidase, and then stained
with the selected antibodies using a standard streptavidin-
biotin detection system. A section without primary antibody
was included as a negative control and known positive cont-
rols were included for each antibody.
Each section was scored by three separate observers (LGB,
BGS, FGH) without knowledge of the patients prognosis and
without reference to each other. The following scoring system
was adopted for all the antibodies except PCIO and S100: no
staining = 0, 1-25% of tumour cells stained = 1, 26-75%
= 2,>75% = 3. No adjustment was made for intensity of
staining.
PC1O stains an antigen on proliferating nuclei, identifying
the number of cells in S phase. The number of positively
stained nuclei per hundred tumour cells were counted in two
random high power fields and this was expressed as a mean
of the two counts. The S100-stained sections were scored by
counting the number of positively stained dendritic cells
within two random high power fields of the tumour and this
was expressed as a mean: none present = 0, Less than 2 = 1,
Greater than 2 = 2.
Results
Results of staining with the antibodies are shown in Figures
1-3. The majority of tumours showed strong staining with
AUA1 (cluster 2). There was no difference between the LTS
and STS groups. LP34 was generally negative, showing no
discrimination in the two groups. HMFG2 showed equal and
variable expression in tumours from both LTS and STS
groups with 54% of cases showing no expression at all.
MBR1 showed a pattern of staining and overall results very
similar to those of HMFG2. CEA was expressed in less than
50% of tumours in the study and there was no difference in
staining pattern between LTS and STS groups.
NSE was demonstrated in less than 50% of cases overall
and those which did stain showed similar results for both the
LTS and the STS group (Figure 2). Chromagranin expression
was present in approximately 40% of cases and the distribu-
tion of positive cases showed no difference between the LTS
and STS groups (Figure 2). Our previous report with HNK1
suggested that lack of staining may be associated with a poor
prognosis (Sheppeard et al., 1987), but the present results
show no significant association of lack of staining with either
the LTS or the STS group (Figure 2).
SWA20 expression on SCLC was variable (Figure 3) with
no relationship to prognostic category. In a small number of
cases in both study groups occasional S100 positive dendritic
cells were seen (Table III). Results with PC10, an antibody to
PCNA (proliferating cell nuclear antigen), were uninterpret-
able in most of our cases because of the nuclear crush
artefact commonly present in fibre-optic biopsies of
SCLC.
Discussion
There have been many attempts to relate biological charac-
teristics of SCLC to prognosis. Cytomorphological character-
istics of the tumour have been examined (Burdon et al., 1979;
Carney et al., 1981; Vollmer et al., 1985; Hirsch et al., 1988)
but the evidence that the tumours with a large cell compon-
ent have a worse prognosis is not convincing. Serum markers
such as NSE (Harding et al., 1990) are related to prognosis
but appear to be indicators of mass of disease rather than
independent predictors of outcome. The same has been sug-
gested for CEA (Sculier et al., 1985; Laberge et al., 1987),
although a recent analysis of surgically resected tumours
suggests that presence of CEA is an adverse prognostic
feature independent of stage (Ruckdeschel et al. 1991). Other
aspects of immunophenotype have been studied by Allan et
al. (1987) who provided some evidence that expression of
HMFG2 might be associated with a worse prognosis, and
Hamid et al. (1987) who claimed a five fold increase in
survival in surgically resected SCLC which did not show
staining with an intibody to the C terminal peptide of human
probombesin, also Martignone et al. (1989) who demon-
Table II Antibodies used in initial screen, and those (*) used in definitive assessment
Antibody Type Source Antigen
MOC21 mAb de Leij Cluster la
123C3 mAb Mooi Probably Cluster la
AUA1a mAb ICRF Cluster 2
HMFG2a mAb ICRF MUC Glycoprotein
SM3 mAb ICRF Stripped protein core of MUC
HNK1a mAb ICRF NCAM but not Cluster I
LP34a mAb ICRF Cytokeratin
PCIOa mAb ICRF Proliferating cell nuclear antigen
HNK901 mAb Griffin NCAM but not Cluster 1
SWA4 mAb Stahel Cluster 5
SWA20a mAb Stahel Clsuter 5a
B5 mAb Freedman Proliferation marker on B cells
MBRIa mAb Menard Membrane glycolipid on breast cancer
and normal breast epithelial cells
CEAa mAb Dako CEA
S100a poly Dako S100 protein
NSEa poly Dako Neurone specific enolase
Chromagranin* mAb Dako Neuroscretory granule protein
Abbreviations: MUC: Mucin. NCAM: Neural cell adhesion molecule. CEA:
Carcino-embryonic antigen. NSE: Neurone-specific enolase. Cluster 1 (etc) refers to notations
of the two small cell lung cancer antigen workshops (Souhami et al., 1991).AN IMMUNOHISTOCHEMICAL INVESTIGATION OF DIAGNOSTIC BIOPSY MATERIAL 549
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Figure 1 Each set of histograms shows the % of cases which fell
into each of the 4 categories of % cells stained. Solid bars are
long term survivors (LTS) and hatched bars are short term
survivors (STS). Data are for AUAI, LF34, HMFG2, MBRI,
CEA. The momenclature of the antibodies is given in Table
II.
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Figure 2 Each set of histograms shows the % of cases which fell
into each of the four categories of % cells stained. Solid bars are
long term survivors (LTS) and hatched bars are short term
survivors (STS). Data are for NSE, Chromogranin (CHR) and
HNK1.
strated an inverse association between expression of the
antigen recognised by MRB1 and overall survival in 63
unselected cases of SCLC.
There are many hidden biases in retrospective analyses of
prognosis in cancer. In the usual analysis, tumours from a
heterogenous group of patients, who have been treated in
many different ways, are examined and the results compared
with outcome. Such analyses often are unable to exclude
treatment effects or the effects of case selection, and fre-
quently do not indicate if the measurement has been made
without knowledge of outcome or how missing data have
been handled. Multiple analyses on the same data set add to
the likelihood of chance, and false, associations.
In the present study we have tried to avoid some of these
difficulties. The groups of patients have been taken at the
extremes of prognosis (survival < 3 months or > 2 years)
since, if no difference is detectable, it seems unlikely that one
will be detected from a population with a wide distribution
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Figure 3 Each set of histograms shows the % of cases which fell into each of the four categories of % cells stained. Solid bars are
long term survivors (LTS) and hatched bars are short term survivors (STS). Data are for antibody SWA20.
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Table III Number of S100 positive dendrite cells within tumours as
either negative, less than two per high power field, or more than two
high power field. The first column shows the results in long term
survivors (LTS) and the second column in short term survivors
(STS)
s1oo
LTS STS
Neg 25 37
<2/HPF 8 2
>2/HPF 3 2
of prognosis. Each short survivor was the next age and sex
matched case entered into the same treatment trial as the
long survivor. In this way we have attempted to minimise
treatment effects. The patients whose specimens were ade-
quate appeared to be representative of the larger group as
judged by age and sex. Finally, the slides were read and
scored by three independent observers without knowledge of
outcome.
Antibodies used in this study were selected to include
markers previously reported as being related to prognosis in
SCLC and reagents recognising neuroendocrine and epithelial
antigens previously identified on SCLC. AUA1 binds to a
4OKd membrane glycoprotein (Spurr et al., 1986; Strnad et
al., 1989), designated as Cluster 2 in the Lung Cancer
Antibody Workshops (Souhami et al., 1991). The antigen
appears to be a homologue of the cell adhesion protein
nidogen (Simon et al., 1990). LP34 recognises cytokeratins 5,
8, 16, 10 and 14, which are expressed by epithelia showing
squamous and glandular differentiation (Lane & Alexander,
1990).
HMFG2 recognises an epitope on a large 180Kd epithelial
mucin which is expressed on normal and lactating breast
epithelium and breast carcinoma cells. The lack ofexpression
of this antigen in over fifty per cent of our cases is of interest
since it has been a target antigen for immunolocalisation
(Epenetos et al., 1982). MBR1, like HMFG2, was initially
raised and studied in the context of breast carcinoma.
CEA is one of the most widely studied tumour-associated
antigens which has recently been shown to belong to the
immunoglobulin superfamily of cell adhesion molecules (Pig-
natelli et al., 1990). It is strongly expressed in a wide range of
adenocarcinomas (Sheahan et al., 1990), and in just over half
of small cell lung cancers (Bepler et al., 1989). The gamma
dimer of NSE, a glycolytic enzyme found in the brain, has
been widely used as a marker of neuroendocrine
differentiation in tumours (Sheppard et al., 1984). Chromo-
granin A is a soluble protein in dense core granules and has
been demonstrated immunohistochemically in approxim ately
50% of SCLC in most reported series (Wilson & Lloyd,
1984). HNK1 has been shown to be expressed on SCLC,
carcinoids, some adenocarcinomas, natural killer cells and
neural tissues, and belongs to the CD54 category ofleucocyte
differentiation antigens which is an epitope ofNCAM (Kruse
et al., 1984).
SWA20 (designated as Cluster 5) is an antibody which
shows a mixed neural and epithelial reactivity (Waibel et al.,
1988). S1OO is a brain protein which has a wide tissue distri-
bution including Langerhans cells. Several studies on the
presence and extent of these cells within other malignant
tumours, and the relationship of their distribution to prog-
nosis, have been carried out (Fox et al., 1989).
The results of this study do not confirm previous findings
(Allan et al., 1987; Hamid et al., 1987; Martignone et al.,
1989, Ruckdeschel et al., 1991) that the use of immunohisto-
chemistry can identify patients with a good or bad prognosis
with SCLC. This negative result must itself be interpreted
cautiously. Firstly we examined mainly fibre-optic broncho-
scopy specimens which, of course, may not represent the
whole tumour. Nevertheless these are the specimens which
the pathologist receives in the vast majority of cases and on
which the clinician makes a judgement about treatment. Pro-
gnostic indicators based on surgically resected SCLC will be
of very limited value. Secondly the panel clearly does not
represent all possible antigens on SCLC. The neural cell
adhesion molecule (NCAM) designated as Cluster 1 in the
Lung Cancer Workshops (Souhami et al., 1991) is a marker
indicative ofthe neuroendocrine status ofthe tumour. Unfor-
tunately it is lost in formalin fixation unless zinc sulphate is
added (Tome et al., 1990) and so could not be used in this
study. Nevertheless Chromogranin, HNK1 and NSE are
neuroendocrine markers and showed no relationship to prog-
nosis. This data from the present study cannot however be
regarded as conclusive on this point and further, prospective,
studies are needed.
For the present it does not appear that any immunohisto-
chemical staining can be recommended as a valuable addition
to the routine diagnosis of SCLC, or to the other clinical and
investigational findings on which a judgement about prog-
nosis and treatment is made.
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